Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 36163978
[No title available]
[No authors listed] [No authors listed] PMID: 36163755
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S, Cortes JE, Krämer A, Levis MJ, Martinelli G, Perl AE, Russell NH, Arunachalam M, Santos CD, Gammon G, Lesegretain A, Mires DE, Pham H, Wang Y, Khaled SK. Ganguly S, et al. Among authors: lesegretain a. Transplant Cell Ther. 2021 Feb;27(2):153-162. doi: 10.1016/j.bbmt.2020.09.036. Epub 2020 Oct 2. Transplant Cell Ther. 2021. PMID: 33017662 Free article.
FLT3 inhibitors added to induction therapy induce deeper remissions.
Levis M, Shi W, Chang K, Laing C, Pollner R, Gocke C, Adams E, Berisha F, Lameh J, Lesegretain A. Levis M, et al. Among authors: lesegretain a. Blood. 2020 Jan 2;135(1):75-78. doi: 10.1182/blood.2019002180. Blood. 2020. PMID: 31722002 Free article. Clinical Trial. No abstract available.
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. DiNardo CD, et al. Among authors: lesegretain a. Cancer Med. 2024 Jul;13(14):e70028. doi: 10.1002/cam4.70028. Cancer Med. 2024. PMID: 39030997 Free PMC article. Clinical Trial.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Among authors: lesegretain a. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Jia Y, Zhang W, Basyal M, Chang KH, Ostermann L, Burks JK, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M. Jia Y, et al. Among authors: lesegretain a. Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21. Leukemia. 2023. PMID: 37085610 Free PMC article. No abstract available.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. Gounder MM, et al. Among authors: lesegretain a. J Clin Oncol. 2023 Mar 20;41(9):1714-1724. doi: 10.1200/JCO.22.01285. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669146 Free PMC article. Clinical Trial.
11 results